程序性死亡配体1在胃癌组织中的表达及其临床意义

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (2259 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the expression level of programmed death ligand 1(PDL1) in patients with gastric cancer and its clinical value. Methods: The expression of PDL1 was detected by immunohistochemical staining in 76 paraffinembedded tissues and 30 adjacent nontumorous tissues of patients with gastric cancer, and the relationship between the expression of PDL1 and clinicopathological features of gastric cancer patients was analyzed. Results: The positivity rate of PDL1 expression in gastric cancer ［52.6%(40/76)］ was significantly higher than that in adjacent nontumorous tissues［23.3%(7/30),Z=3.104, P=0.002］. The expression of PDL1 in patients with gastric cancer was correlated with differentiation degree(χ2=8.740,P=0.013) and infiltration depth(χ2=8.960,P=0.030), in addition, the expression of PDL1 in gastric cancer with clinical staging of stage Ⅲ+stage Ⅳ was significantly higher than that of stage Ⅰ+stage Ⅱ (χ2=4.133, P=0.042). Conclusion: PDL1 was highly expressed in gastric cancer， which might be considered as a biological indicator for the differentiation and invasion of gastric cancer.

Received: 08 October 2016

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2017/V27/I02/158

[1\]Dong H, Strome SE, Salomao DR, et al. Tumorassociated B7H1 promotes Tcell apoptosis: a potential mechanism of immune evasion\[J\]. Nat Med, 2002, 8(8): 793-800.
\[2\]Thompson RH, Gillett MD, Cheville JC , et al. Costimulatory B7H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target\[J\]. Proc Natl Acad Sci U S A, 2004, 101(49): 17174-17179.
\[3\]Konishi J, Yamazaki K, Azuma M, et al. B7H1 expression on nonsmall cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD1 expression\[J\]. Clin Cancer Res, 2004, 10(15): 5094-5100.
\[4\]Ohigashi Y,Sho M,Yamada Y, et al. Clinical significance of programmed death1ligand1 and programmed death1ligand2 expression in human esophageal cancer\[J\]. Clin Cancer Res, 2005, 11(8): 2947-2953.
\[5\]Zhang J, Gao J, Nie J, et al. Circulating PDL1 in NSCLC patients and the correlation between the level of PDL1 expression and the clinical characteristics\[J\]. Thorac Cancer, 2015, 6(4): 534-538.
\[6\]Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7H1 (PDL1) on paraffinembedded slides of pancreatic adenocarcinoma tissue\[J\]. J Vis Exp, 2013,(71). pii: 4059.
\[7\]Abiko K, Mandai M, Hamanishi J, et al. PDL1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction\[J\]. Clin Cancer Res, 2013, 19(6): 1363-1374.
\[8\]Soliman H, Khalil F, Antonia S. PDL1 expression is increased in a subset of basal type breast cancer cells\[J\]. PLoS One, 2014, 9(2): e88557.
\[9\]Vlahovic G, Fecci PE, Reardon D, et al. Programmed death ligand 1(PDL1) as an immunotherapy target in patients with glioblastoma\[J\]. Neuro Oncol, 2015, 17(8 ): 1043-1045.
\[10\]Zhu H, Qin H, Huang Z, et al. Clinical significance of programmed death ligand1 (PDL1) in colorectal serrated adenocarcinoma\[J\]. Int J Clin Exp Pathol, 2015, 8(8): 9351-9359.
\[11\]Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7H1(PDL1) and increase expression after stimulation with IFNγ and TLR ligands via a MyD88, TRAF6, and MEKdependent pathway\[J\]. Blood, 2007, 110(1): 296-304.
\[12\]Bajinska J, Viry E, Paggetti J, et al. The critical role of the tumor microenvironment in shaping natural killer cellmediated antitumor immunity\[J\]. Front Immunol，2013，4:490.
\[13\]Topalian SL, Drake CG, Pardoll DM. Targeting the PD1/B7H1(PDL1) pathway to activate antitumor immunity\[J\]. Curr Opin Immunol, 2012, 24(2): 207-212.
\[14\]韩奕文，徐蓉蔓，陈志红，等.胃癌细胞株及胃癌组织程序性死亡受体1的表达［J］.江苏大学学报（医学版），2016，26（5）：449-451.
\[15\]Wang J, Jensen Mi, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains\[J\]. Hum Gene Ther, 2007, 18(8): 712-725.
\[16\]Powles T, Eder JP, Fine GD, et al. MPDL3280A (antiPDL1) treatment leads to clinical activity in metastatic bladder cancer\[J\]. Nature, 2014, 515(7528): 558-562.
\[17\]Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer\[J\]. N Engl J Med, 2012, 366(26): 2455-2465.